Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05712200 · ClinicalTrials.gov registry record · Phase 3
Study to evaLuate the effIcacy and Safety of abeLacimab in High-risk Patients With Atrial Fibrillation Who Have Been Deemed Unsuitable for Oral antiCoagulation (LILAC-TIMI 76)
A Phase 3 study of Atrial Fibrillation (AF), sponsored by Anthos Therapeutics.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 1,900
- Enrollment target
- 20
- Study locations
NCT05712200 is a Phase 3 study of Atrial Fibrillation (AF) that is actively recruiting participants, run by Anthos Therapeutics. The registered enrollment target is 1,900 participants, above the 608-participant average among 17 other Atrial Fibrillation (AF) trials with a reported enrollment target (213% higher). The trial reports 20 study locations across 3 states.
The verdict
NCT05712200, a Phase 3 study of Atrial Fibrillation (AF), is actively recruiting participants, sponsored by Anthos Therapeutics.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 1,900 participants
- Enrollment target
- 20
- Study locations
Study Summary
A study to evaluate the effect of abelacimab relative to placebo on the rate of ischemic stroke or systemic embolism (SE) in patients with Atrial Fibrillation (AF) who have been deemed by their responsible physicians or by their own decision to be unsuitable for oral anticoagulation therapy.
Conditions Studied
Interventions
- DRUG Placebo
- BIOLOGICAL Abelacimab
Study Locations (20)
California
- Anthos Investigative Site 9929 - Huntington Beach
- Anthos Investigative Site 9959 - Imperial
- Anthos Investigative Site 9921 - Lancaster
- Anthos Investigative Site 1078 - Loma Linda
- Anthos Investigative Site 1077 - Los Angeles
- Anthos Investigative Site 1015 - Northridge
- Anthos Investigative Site 1070 - Redding
- Anthos Investigative Site 1071 - San Dimas
- Anthos Investigative Site 1076 - Santa Ana
- Anthos Investigative Site 9938 - Santa Rosa
- Anthos Investigative Site 9908 - South Gate
- Anthos Investigative Site 9907 - Vista
Alabama
- Anthos Investigative Site 1040 - Birmingham
- Anthos Investigational site 9939 - Birmingham
- Anthos Investigative Site 9947 - Birmingham
- Anthos Investigative Site 1041 - Mobile
Arizona
- Anthos Investigative Site 1089 - Gilbert
- Anthos Investigative Site 1099 - Peoria
- Anthos Investigative Site 9906 - Phoenix
- Anthos Investigative Site 9927 - Yuma
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,900 participants |
| Start Date | 2022-12-27 |
| Est. Completion | 2026-10-31 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05712200
The ClinicalTrials.gov registry entry for NCT05712200 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 1,900 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 608-participant average among 17 other Atrial Fibrillation (AF) trials with a reported enrollment target (213% higher). The listed sponsor is Anthos Therapeutics, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Atrial Fibrillation (AF) appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT05712200 reports 20 study locations spanning 3 distinct geographic areas - top geographies include California, Alabama, Arizona.
Frequently Asked Questions
What is clinical trial NCT05712200 about?
NCT05712200 is a clinical study titled "Study to evaLuate the effIcacy and Safety of abeLacimab in High-risk Patients With Atrial Fibrillation Who Have Been Deemed Unsuitable for Oral antiCoagulation (LILAC-TIMI 76)". A study to evaluate the effect of abelacimab relative to placebo on the rate of ischemic stroke or systemic embolism (SE) in patients with Atrial Fibrillation (AF) who have been deemed by their responsible physicians or by their own decision to be unsuitable for oral anticoagulation therapy.
What is the current status of trial NCT05712200?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 1,900 participants. The study started on 2022-12-27. Estimated completion is 2026-10-31.
What conditions does trial NCT05712200 study?
This clinical trial studies the following conditions: Atrial Fibrillation (AF).
What interventions are being tested in trial NCT05712200?
The interventions under investigation include: Placebo (DRUG), Abelacimab (BIOLOGICAL).
Who is sponsoring clinical trial NCT05712200?
This trial is sponsored by Anthos Therapeutics, which has 6 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05712200 being conducted?
This trial has 20 study locations across Alabama, Arizona, California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Atrial Fibrillation (AF)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Digitally Rendered Interventions And Knowledge To Limit Ethanol-Associated Atrial Fibrillation Severity
RECRUITING · NA
-
Incidence of Long-TeRm Atrial Fibrillation After Acute Illness
RECRUITING
-
Disrupted Sleep and Concurrent Ectopy or Atrial Fibrillation
RECRUITING · NA
-
Perioperative Anticoagulant Use for Surgery Evaluation -Virtual Visit (PAUSE-Virtual)
RECRUITING
-
Cardiovascular Innovation & Research Institute 's NEXUS Registry, the Whole is Greater Than the Parts.
RECRUITING
-
Perioperative Anticoagulant Use for Surgery Evaluation -2 (PAUSE-2) Study Patients Receiving a Direct Oral Anticoagulant (DOACs-Dabigatran, Rivaroxaban, Apixaban or Edoxaban) and Needing Elective High-Bleed-Risk Surgery or an Invasive Procedure
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.